Therapeutic | Lebrikizumab |
Target | IL13 |
Heavy Chain | QVTLRESGPALVKPTQTLTLTCTVSGFSLSAYSVNWIRQPPGKALEWLAMIWGDGKIVYNSALKSRLTISKDTSKNQVVLTMTNMDPVDTATYYCAGDGYYPYAMDNWGQGSLVTVSS |
Light Chain | DIVMTQSPDSLSVSLGERATINCRASKSVDSYGNSFMHWYQQKPGQPPKLLIYLASNLESGVPDRFSGSGSGTDFTLTISSLQAEDVAVYYCQQNNEDPRTFGGGTKVEIK |
100% seqID Fv Structure | 4i77 [Fvs: HL] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 4i77 [Fvs: HL] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G4 |
Highest Clinical Trial (June '19) | Phase-III |
Estimated Status (June '19) | Active |
Recorded Developmental Technology | na |
INN Year Proposed | 2009 |
INN Year Recommended | 2010 |
Companies Involved | Chugai Pharmaceutical, Comprehensive Clinical Research Network, Dermira, Genentech, Roche, Tanox |
Conditions Approved | na |
Conditions Active | Atopic dermatitis |
Conditions Discontinued | Asthma, Chronic obstructive pulmonary disease, Hodgkin's disease, Idiopathic pulmonary fibrosis |
Notes |